ACS Pharmacotherapy Personalization Tool
Patient and treatment factors
Complete all six fields, then calculate the considerations.
Clinical context and limitations
This tool organizes selected pharmacotherapy considerations for adults with ACS. It does not calculate drug doses or independently establish eligibility for any treatment.
Important checks before prescribing
- Confirm diagnosis, reperfusion strategy, timing, hemodynamic stability, and any planned invasive procedure.
- Review bleeding history, prior stroke or TIA, body weight, allergies, drug interactions, and contraindications to antithrombotic therapy.
- Verify renal function and potassium, particularly before anticoagulants, ACE inhibitors/ARBs, or mineralocorticoid receptor antagonists.
- Reassess antithrombotic combinations and duration after PCI when long-term oral anticoagulation is required.
- Do not initiate beta-blockers during cardiogenic shock or acute decompensated heart failure; reassess once stable.
References
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology. 2025.
2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44:3720–3826.
2025 ACS Guideline: Top Things to Know and supporting clinical guidance.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.